16 January 2026 - The treatment barriers will likely be significantly lowered for patients with rare diseases in Korea, such as AL amyloidosis, myelofibrosis, and spinal muscular atrophy, as well as those with severe illnesses.

Drugs for AL amyloidosis, myelofibrosis, severe eosinophilic asthma, and spinal muscular atrophy have cleared a significant hurdle for national health insurance coverage, having been recognised as appropriate for reimbursement application and for an expanded scope of coverage.

Read Korea Biomedical Review article